Collectively, these findings supported the activation of the IL-6/STAT3 pathway and aggressive cancer stem-like phenotype in IL-6high/ESE3low tumors and suggested that these tumors could be targeted by therapy opposing this pathway. The gene discussed is STAT3; the disease is cancer.